Abemaciclib
Brand names: Verzenio · Active ingredient: Abemaciclib
In short: VERZENIO® (abemaciclib) is indicated: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of rec
What is Abemaciclib used for?
VERZENIO® (abemaciclib) is indicated:
in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence.
VERZENIO (abemaciclib) is indicated:
in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer.
in combination with fulvestrant for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.
in combination with imlunestrant for the treatment of adults with estrogen receptor (ER)-positive, HER2-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA authorized test, with disease progression following at least one line of endocrine therapy .
as monotherapy for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.
Abemaciclib dosage
VERZENIO in Combination with Imlunestrant
Select patients for treatment of ER-positive, HER2-negative advanced or metastatic breast cancer with VERZENIO in combination with imlunestrant based on the presence of ESR1 mutation(s) in a plasma specimen using an FDA authorized test .
Information on FDA-authorized tests for the detection of ESR1 mutations in breast cancer is available at: https://www.fda.gov/CompanionDiagnostics.
VERZENIO in Combination with Fulvestrant, Tamoxifen, Imlunestrant or An Aromatase Inhibitor
The recommended dosage of VERZENIO is 150 mg orally twice daily.
For early breast cancer, continue VERZENIO until completion of 2 years of treatment or until disease recurrence, or unacceptable toxicity.
For advanced or metastatic breast cancer, continue treatment until disease progression or unacceptable toxicity.
For premenopausal and perimenopausal women and men treated with VERZENIO in combination with an aromatase inhibitor, imlunestrant, or fulvestrant should be treated with a gonadotropin-releasing hormone agonist (GnRH) according to current clinical practice standards.
Refer to the Prescribing Information for the recommended dose of the fulvestrant, tamoxifen, imlunestrant or aromatase inhibitor being used.
VERZENIO Monotherapy
The recommended dosage of VERZENIO as monotherapy is 200 mg orally twice daily.
Administration
Take VERZENIO orally, with or without food, at approximately the same times every day .
Swallow VERZENIO tablets whole. Do not chew, crush, or split tablets. Do not ingest VERZENIO tablets if broken, cracked, or otherwise not intact.
Missed Dose
If a dose of VERZENIO is missed, skip the missed dose and take the next dose at the next scheduled time.
Vomited Dose
If vomiting occurs after taking a dose of VERZENIO, do not take an additional dose. Take the next dose at the next scheduled time.
The recommended VERZENIO dose reductions for adverse reactions are provided in Table 1. Permanently discontinue VERZENIO for patients unable to tolerate 50 mg twice daily.
Dosage Level | VERZENIO Dose in
Combination with Fulvestrant, Tamoxifen, Imlunestrant or an Aromatase Inhibitor | VERZENIO Dose
for Monotherapy
Recommended starting dosage | 150 mg twice daily | 200 mg twice daily
First dosage reduction | 100 mg twice daily | 150 mg twice daily
Second dosage reduction | 50 mg twice daily | 100 mg twice daily
Third dosage reduction | not applicable | 50 mg twice daily
The recommended VERZENIO dosage modifications for adverse reactions are provided in Tables 2-7.
Abbreviation: CTCAE = Common Terminology Criteria for Adverse Events.
a If blood cell growth factors are required, withhold VERZENIO dosage for at least 48 hours after the last dose of blood cell growth factor and until toxicity resolves to ≤Grade 2. …
How to take Abemaciclib — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Diarrhea
VERZENIO may cause diarrhea, which may be severe in some cases .
Early identification and intervention is critical for the optimal management of diarrhea. Instruct patients that at the first sign of loose stools, they should start antidiarrheal therapy (for example, loperamide) and notify their healthcare provider for further instructions and appropriate follow up.
Encourage patients to increase oral fluids.
If diarrhea does not resolve with antidiarrheal therapy within 24 hours to ≤Grade 1, suspend VERZENIO dosing .
Neutropenia
Advise patients of the possibility of developing neutropenia and to immediately contact their healthcare provider should they develop a fever, particularly in association with any signs of infection .
Interstitial Lung Disease/Pneumonitis
Advise patients to immediately report new or worsening respiratory symptoms .
Hepatotoxicity
Inform patients of the signs and symptoms of hepatotoxicity. Advise patients to contact their healthcare provider immediately for signs or symptoms of hepatotoxicity . …
Warnings & precautions
Do not take this medicine if: None.
Severe diarrhea associated with dehydration and infection occurred in patients treated with VERZENIO.
Across five clinical trials in 3899 patients, diarrhea occurred in 81% to 90% of patients who received VERZENIO. Grade 3 diarrhea occurred in 8% to 20% of patients receiving VERZENIO .
Most patients experienced diarrhea during the first month of VERZENIO treatment. The median time to onset of the first diarrhea event ranged from 6 to 8 days; and the median duration of Grade 2 and Grade 3 diarrhea ranged from 6 to 11 days and 5 to 8 days, respectively. Across trials, 19% to 26% of patients with diarrhea required a VERZENIO dose interruption and 13% to 23% required a dose reduction.
Instruct patients to start antidiarrheal therapy such as loperamide at the first sign of loose stools, increase oral fluids, and notify their healthcare provider for further instructions and appropriate follow up . For Grade 3 or 4 diarrhea, or diarrhea that requires hospitalization, withhold VERZENIO until resolution to ≤Grade 1, and then resume VERZENIO at the next lower dose .
Neutropenia, including febrile neutropenia and fatal neutropenic sepsis, occurred in patients treated with VERZENIO.
Across five clinical trials in 3899 patients, neutropenia occurred in 37% to 51% of patients receiving VERZENIO. A Grade ≥3 decrease in neutrophil count (based on laboratory findings) occurred in 19% to 32% of patients receiving VERZENIO. Across trials, the median time to the first episode of Grade ≥3 neutropenia ranged from 29 days to 34 days, and the median duration of Grade ≥3 neutropenia ranged from 10 days to 16 days .
Febrile neutropenia has been reported in <1% of patients receiving VERZENIO across trials. Two deaths due to neutropenic sepsis were observed in MONARCH 2. Inform patients to promptly report any episodes of fever to their healthcare provider . …
Abemaciclib side effects
The following adverse reactions are discussed in greater detail in other sections of the labeling:
Diarrhea .
Neutropenia .
Interstitial Lung Disease (ILD) or Pneumonitis .
Hepatotoxicity .
Venous Thromboembolism .
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety population described in the Warnings and Precautions reflect exposure to VERZENIO in 3899 patients from five clinical trials including 132 patients treated with VERZENIO as monotherapy at 200 mg twice daily in MONARCH 1, 3767 patients treated with VERZENIO in combination with fulvestrant, tamoxifen, imlunestrant or an aromatase inhibitor at 150 mg twice daily in MONARCH 2, monarchE, EMBER-3, and MONARCH 3. The median duration of exposure ranged from 4.5 months in MONARCH 1 to 24 months in monarchE. The most common adverse reactions (incidence ≥20%) across clinical trials were: diarrhea, infections, neutropenia, fatigue, abdominal pain, nausea, leukopenia, anemia, and vomiting. …
Drug interactions
CYP3A Inhibitors
Strong and moderate CYP3A4 inhibitors increased the exposure of abemaciclib plus its active metabolites to a clinically meaningful extent and may lead to increased toxicity.
Ketoconazole
Avoid concomitant use of ketoconazole. Ketoconazole is predicted to increase the AUC of abemaciclib by up to 16-fold .
Other Strong CYP3A Inhibitors
In patients with recommended starting doses of 200 mg twice daily or 150 mg twice daily, reduce the VERZENIO dose to 100 mg twice daily with concomitant use of strong CYP3A inhibitors other than ketoconazole. In patients who have had a dose reduction to 100 mg twice daily due to adverse reactions, further reduce the VERZENIO dose to 50 mg twice daily with concomitant use of strong CYP3A inhibitors. If a patient taking VERZENIO discontinues a strong CYP3A inhibitor, increase the VERZENIO dose (after 3-5 half-lives of the inhibitor) to the dose that was used before starting the inhibitor. Patients should avoid grapefruit products .
Moderate CYP3A Inhibitors
With concomitant use of moderate CYP3A inhibitors, monitor for adverse reactions and consider reducing the VERZENIO dose in 50 mg decrements as demonstrated in Table 1, if necessary. …
About this medicine
Abemaciclib is a kinase inhibitor for oral administration. It is a white to yellow powder with the empirical formula C27H32F2N8 and a molecular weight 506.59.
The chemical name for abemaciclib is 2-Pyrimidinamine, N-[5-[(4-ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-. Abemaciclib has the following structure:
VERZENIO (abemaciclib) tablets are provided as immediate-release oval white, beige, or yellow tablets. Inactive ingredients are as follows: Excipients—microcrystalline cellulose 102, microcrystalline cellulose 101, lactose monohydrate, croscarmellose sodium, sodium stearyl fumarate, silicon dioxide. Color mixture ingredients—polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, iron oxide yellow, and iron oxide red.
How it works: Abemaciclib is an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6). These kinases are activated upon binding to D-cyclins. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID be4bc0de-0fdc-4d46-8d25-be43c79e6a06. Read the full official label on DailyMed.
Related medicines
Levothyroxine Ergocalciferol Estradiol Ethinyl Estradiol and Norethindrone Alendronate Testosterone Thyroid Norethindrone